Associated Papers
mTOR Variants Activation Discovers PI3K-like Cryptic Pocket, Expanding Allosteric, Mutant-Selective Inhibitor Designs.
Liu Y et al.
Journal of Chemical Information and Modeling, 2025
The mTOR pathway controls phosphorylation of BRAF at T401.
Christen D et al.
Cell Communication and Signaling : Ccs, 2024
mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies.
Sztankovics D et al.
Pathology Oncology Research : Por, 2024
Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis.
El-Tanani M et al.
Life Sciences, 2023
mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion.
Liu HJ et al.
Nature Communications, 2023
Intracellular energy controls dynamics of stress-induced ribonucleoprotein granules.
Wang T et al.
Nature Communications, 2022
Is Focal Cortical Dysplasia/Epilepsy Caused by Somatic MTOR Mutations Always a Unilateral Disorder?
Guerrini R et al.
Neurology. Genetics, 2021
Convergent and Divergent Mechanisms of Epileptogenesis in mTORopathies.
Nguyen LH et al.
Frontiers in Neuroanatomy, 2021
mTOR: Role in cancer, metastasis and drug resistance.
Murugan AK
Seminars in Cancer Biology, 2019
Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy.
Di Cosimo S et al.
Cancers, 2019
Pathological mTOR mutations impact cortical development.
Tarkowski B et al.
Human Molecular Genetics, 2019
Identification and characterization of two novel oncogenic mTOR mutations.
Murugan AK et al.
Oncogene, 2019
The prognostic effects of somatic mutations in ER-positive breast cancer.
Griffith OL et al.
Nature Communications, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J et al.
Genome Medicine, 2018
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
Karube K et al.
Leukemia, 2018
Constitutive Activation Mutant mTOR Promote Cone Survival in Retinitis Pigmentosa Mice.
Rajala A et al.
Advances in Experimental Medicine and Biology, 2018
Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability.
Tatton-Brown K et al.
American Journal of Human Genetics, 2017
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
Fan Q et al.
Cancer Cell, 2017
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Xu J et al.
The Journal of Clinical Investigation, 2016
Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.
Yamaguchi H et al.
Cancer Science, 2015
Molecular genetics of clear-cell renal cell carcinoma.
Brugarolas J
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
Wagle N et al.
Cancer Discovery, 2014
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
Grabiner BC et al.
Cancer Discovery, 2014
Mutations in critical domains confer the human mTOR gene strong tumorigenicity.
Murugan AK et al.
The Journal of Biological Chemistry, 2013
Activating mutations of TOR (target of rapamycin).
Hardt M et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms, 2011
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.
Sato T et al.
Oncogene, 2010
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.
Dalgliesh GL et al.
Nature, 2010